.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Federal Trade Commission
Merck
Farmers Insurance
QuintilesIMS
Argus Health
Queensland Health
McKinsey
Medtronic
Chubb

Generated: September 20, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 6,107,458 protect, and when does it expire?


Patent ► Subscribe protects MYCAMINE and is included in one NDA. There has been one Paragraph IV challenge on Mycamine.

This patent has thirty-eight patent family members in twenty-eight countries.

Summary for Patent: ► Subscribe

Title: Cyclic hexapeptides having antibiotic activity
Abstract:This invention relates to new polypeptide compounds represented by the following formula (I): ##STR1## wherein R.sup.1 is as defined in the description and pharmaceutically acceptable salt thereof which have antimicrobial activities (especially, antifungal activities), inhibitory activity on .beta.-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for the prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.
Inventor(s): Ohki; Hidenori (Takarazuka, JP), Tomishima; Masaki (Minoo, JP), Yamada; Akira (Fujiidera, JP), Takasugi; Hisashi (Sakai, JP)
Assignee: Fujisawa Pharmaceutical Co., Ltd. (Osaka, JP)
Application Number:08/809,723
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Astellas
MYCAMINE
micafungin sodium
INJECTABLE;IV (INFUSION)021506-002Mar 16, 2005RXYesYes► Subscribe► SubscribeYY TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS
Astellas
MYCAMINE
micafungin sodium
INJECTABLE;IV (INFUSION)021506-002Mar 16, 2005RXYesYes► Subscribe► SubscribeYY TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABCESSES
Astellas
MYCAMINE
micafungin sodium
INJECTABLE;IV (INFUSION)021506-003Jun 27, 2006RXYesYes► Subscribe► SubscribeYY TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS
Astellas
MYCAMINE
micafungin sodium
INJECTABLE;IV (INFUSION)021506-003Jun 27, 2006RXYesYes► Subscribe► SubscribeYY TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABCESSES
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9420425Oct 17, 1994
United Kingdom9508745Apr 28, 1995
PCT Information
PCT FiledSeptember 29, 1995PCT Application Number:PCT/JP95/01983
PCT Publication Date:April 18, 1996PCT Publication Number: WO96/11210

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,265,536 Cyclic hexapeptides having antibiotic activity► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
HungaryT77736► Subscribe
Finland971397► Subscribe
United Kingdom9508745► Subscribe
Hong Kong1004136► Subscribe
Finland119988► Subscribe
United Kingdom9420425► Subscribe
China1203089► Subscribe
China1168675► Subscribe
Spain2187575► Subscribe
European Patent Office0788511► SubscribeCA 2008 00030Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Johnson and Johnson
Boehringer Ingelheim
Merck
UBS
US Army
Chubb
Covington
Healthtrust
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot